A bioluminescent indicator glows when a cancer drug is active inside the brain, identifying which medications cross the blood-brain barrier.
Researchers at Stanford Medicine discovered the mechanism for a heart condition and developed a drug to treat it.
Researchers created an algorithm to determine if mice have epilepsy and whether they have been treated with seizure drugs.
Researchers from Stanford have developed a wearable sensor to monitor the size of tumors, which could assist new cancer drug evaluations.
Researchers are harnessing an imaging technique called cryogenic electron microscopy to design drugs and better understand disease.
Stanford Medicine magazine explores the molecules behind human biology and how understanding them fuels medical discoveries and innovations.
Researchers at Stanford Medicine are working to develop antivirals to stop the current pandemic and prevent ones.
Stanford researchers are developing a faster way to match each ulcerative colitis patient with the treatment that will work best for them.
Researchers discuss the need for ethics and its integration into research projects that harness artificial intelligence.
A Stanford patient improved greatly after being the first person with sight-threatening thyroid eye disease to receive the drug teprotumumab.
To help us understand muscle loss as we age, a Stanford Medicine research team’s engineered tissue is sent to the International Space Station.
Anthony Oro is devoted to understanding the origin of basal cell carcinomas. Now he's found how some become resistant to a common treatment.
Stanford Medicine researchers have discovered a drug that could potentially be used to stave off SARS-CoV-2, the virus that causes COVID-19.
The Innovative Medicines Accelerator builds on existing programs at Stanford — but fills in gaps to help researchers turn ideas into drugs.
A study provides evidence that the drug azlocillin eliminates the bacteria that cause Lyme disease at the onset of infection in lab mice and cultures.
At a recent Dean's Lecture Series, Dean Lloyd Minor discussed organizational culture and diversity with Emma Walmsley, CEO of GlaxoSmithKline.
